{"schema":"hottub-news/list/v1","item_schema":"hottub-news/item/v1","count":1,"sponsored":0,"items":[{"id":"n_msughiecpj6n4vegaoja","seq":582015,"kind":"article","title":"恒瑞醫藥向諾和授許可 潛在總交易額最高達26億美元","title_en":"Hengrui Medicine grants license to Novartis with potential total transaction value up to $2.6 billion","url":"https://www.bastillepost.com/hongkong/article/16869939-%e6%81%92%e7%91%9e%e9%86%ab%e8%97%a5%e5%90%91%e8%ab%be%e5%92%8c%e6%8e%88%e8%a8%b1%e5%8f%af-%e6%bd%9b%e5%9c%a8%e7%b8%bd%e4%ba%a4%e6%98%93%e9%a1%8d%e6%9c%80%e9%ab%98%e9%81%9426%e5%84%84%e7%be%8e","summary":"恒瑞醫藥(01276)發公告，披露與諾和達成授權許可協議，向對方授予HRS-1596在大中華地區以外全球開發、生產與商業化的獨家權利。 公告指出，恒瑞醫樂在交易在潛在獲得金額最高達26億美元，包括3億美元首付款，以及達成相關開發、註冊和商業化里程碑後獲得的付款。該公司尚有資格根據HRS-1596在授權區域內淨銷售額，收取相應銷售提成。 HRS-1596 是一款恒瑞自主研發的GLP-1/GIP雙受體激動劑。HRS-1596旨在通過抑制食欲、促進胰島素分泌和改善胰島素敏感性等多重機制，實現減重和改善血糖控制，具有用於肥胖症、2型糖尿病及其他代謝性疾病的潛力。","published":"2026-09-29T04:39:40Z","seen":"2026-09-29T05:10:20Z","lang":"zh","country":"HK","source":{"id":"kite-bastillepost-com-c7bf21","name":"bastillepost.com","domain":"bastillepost.com"},"via":"kite-bastillepost-com-c7bf21","topics":["錢財事","恒瑞醫藥(01276)"],"authors":["Tong Po Yan"],"entities":[{"id":"Q24838676","name":"Jiangsu Hengrui Medicine","type":"org"},{"id":"Q507154","name":"Novartis","type":"org"}],"story":"st_msughiecpj6n4vegaoja","category":"economy-business","category_p":0.94,"sentiment":"positive","tone":0.49,"political":0.12}]}